PayPay Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

PayPay Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.18K	Sell	5 -1	-17%	-$466	0.08%	166
2025 Q4	$2.72K	Buy	6 +1	+20%	+$431	0.08%	163
2025 Q3	$1.92K	Buy	5 +1	+25%	+$418	0.07%	171
2025 Q2	$1.78K	Sell	4 -1	-20%	-$461	0.09%	157
2025 Q1	$2.75K	Sell	5 -3	-38%	-$1.4K	0.16%	125
2024 Q4	$3.22K	Buy	+8	New	+$3.71K	0.14%	126

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PayPay Securities's VRTX Position: Q1 2026 in Review

PayPay Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, selling an estimated $466 and leaving 5 shares worth $2.18K. The position accounts for 0.08% of the portfolio, ranked #166.

PayPay Securities first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.22K in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

PayPay Securities held 5 shares of Vertex Pharmaceuticals worth $2.18K as of Q1 2026.
PayPay Securities sold 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $466.
Vertex Pharmaceuticals made up 0.08% of PayPay Securities's portfolio in Q1 2026, its #166 holding.
PayPay Securities first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
PayPay Securities's Vertex Pharmaceuticals position peaked at $3.22K in Q4 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on PayPay Securities's 13F filing for Q1 2026, filed 23 Apr 2026.